InterCure Ltd. (INCR)
NASDAQ: INCR · Real-Time Price · USD
0.9399
+0.0169 (1.83%)
Feb 2, 2026, 10:06 AM EST - Market open
InterCure Revenue
InterCure had revenue of 65.01M ILS in the half year ending June 30, 2025, with 3.40% growth. This brings the company's revenue in the last twelve months to 243.12M, down -10.84% year-over-year. In the year 2024, InterCure had annual revenue of 238.85M, down -32.82%.
Revenue (ttm)
243.12M ILS
Revenue Growth
-10.84%
P/S Ratio
0.72
Revenue / Employee
759,759 ILS
Employees
320
Market Cap
51.62M USD
Revenue Chart
* This company reports financials in ILS.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 238.85M | -116.71M | -32.82% |
| Dec 31, 2023 | 355.55M | -33.13M | -8.52% |
| Dec 31, 2022 | 388.68M | 169.01M | 76.93% |
| Dec 31, 2021 | 219.68M | 154.64M | 237.78% |
| Dec 31, 2020 | 65.04M | 56.11M | 628.60% |
| Dec 31, 2019 | 8.93M | - | - |
| Dec 31, 2018 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Assertio Holdings | 137.35M |
| Rockwell Medical | 75.58M |
| Aytu BioPharma | 63.70M |
| Cumberland Pharmaceuticals | 41.28M |
| Zhengye Biotechnology Holding | 21.46M |
| SCYNEXIS | 2.93M |
| TherapeuticsMD | 2.80M |
| BioXcel Therapeutics | 752.00K |
INCR News
- 3 months ago - InterCure and Cannasoul Sign Strategic Investment and Collaboration Agreements to Advance Cannabis Science and Pharmaceutical Innovation - GlobeNewsWire
- 4 months ago - InterCure Reports First Half 2025 Results with NIS 130 Million in Revenue and Positive Operating Cash Flow - GlobeNewsWire
- 4 months ago - InterCure Announces Strategic Acquisition of ISHI, Unlocking Access to Premium U.S. Cannabis Technology and Brands - GlobeNewsWire
- 9 months ago - InterCure Announces FY2024 Results and Provides Q1 2025 Update: Revenue of NIS 239 Million and Adjusted EBITDA of NIS 24 Million, Strong Start to 2025 - PRNewsWire
- 1 year ago - InterCure Names Alexander Rabinovich as Chairman Replacing Ehud Barak - PRNewsWire
- 1 year ago - InterCure has Secured Funding of NIS 66M to support the recovery of Nir Oz Facility - PRNewsWire
- 1 year ago - Are Investors Missing The Forest? 35% Stock Drop Masks The International Potential Of This Weed Company - Benzinga
- 1 year ago - InterCure Announces First Half of 2024 Results: Revenue of NIS 126 million and Adjusted EBITDA of NIS 21 million - GlobeNewsWire